Is VYNE or XBIO more undervalued in 2026?

CirclFi compares VYNE Therapeutics Inc. (VYNE) and Xenetic Biosciences, Inc. (XBIO) using 13 institutional-grade valuation models. VYNE has a Quality of Company score of 4.6/10 while XBIO scores 6.6/10.

Which is a better buy — VYNE or XBIO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VYNE and XBIO valuations compare?

VYNE at $0.68 and XBIO at $3.15 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VYNE vs XBIO Valuation Comparison 2026 — Intrinsic Value Analysis

VYNE

Pharmaceutical Preparations

VYNE Therapeutics Inc.

Quality

4.6

out of 10

Value Trap

LOW

Price

$0.68

Last close

Models

9/13

Active

XBIO

Pharmaceutical Preparations

Xenetic Biosciences, Inc.

Quality

6.6

out of 10

Value Trap

SAFE

Price

$3.15

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	VYNE Fair Value	VYNE Upside	XBIO Fair Value	XBIO Upside
Bayesian DCF	Intrinsic	$0.58	-14.7%	$2.60	-17.6%
Earnings Power Value	Intrinsic	—	—	$2.84	-4.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.33	+242.3%	$10.00	+217.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VYNE vs XBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VYNE vs XBIO — Which Stock Is More Undervalued?

XBIO scores higher with a 6.6/10 quality rating vs VYNE's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing VYNE Therapeutics Inc. (VYNE) and Xenetic Biosciences, Inc. (XBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VYNE currently trades at $0.68 with a QOC of 4.6/10, while XBIO trades at $3.15 with a QOC of 6.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).